Fundz

Wugen, Inc. reported raising $98.5 Million in an initial SEC Form D filing, from an offering of $172 Million

PRIVATEJul 23, 2021$98.5M of $172M raised

Amount Raised

$98.5 Million

$98.5 Million sold, per SEC Form D (first sale Jul 23, 2021)

Round Type

Venture

St. LouisBiotechnologyresearch

Quick answer

Wugen raised $98.5 Million in a funding round, dated July 23, 2021. Wugen is based in St. Louis, Missouri, United States.

How much did Wugen raise?
Wugen raised $98.5 Million in a funding round on July 23, 2021.
What does Wugen do?
Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
Where is Wugen based and how big is it?
Wugen is based in St. Louis, Missouri, United States. Fundz records about 58 employees.
Who are the decision-makers at Wugen?
Fundz holds 1 contact at Wugen. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in research and Biotechnology around the same time

Companies in the same sectors as Wugen that raised within 45 days of this round, from Fundz verified event records.

  • Aarvik Therapeutics raised $8.3M on September 2, 2021.
  • Linnaeus Therapeutics raised $4.3M (Seed) on August 24, 2021.
  • Arzeda raised $26M on July 22, 2021.
  • Akari Therapeutics raised $12M on July 22, 2021.
  • Kriya Therapeutics raised $100M (Series B) on July 14, 2021.
  • Kriya Therapeutics raised $321M on July 14, 2021.

Who to call at Wugen, and when

A new round usually means Wugen is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Wugen raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Wugen, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Wugen. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Wugen

Location

4260 Forest Park Ave., Suite 100

St. Louis, Missouri, United States

About

Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Wugen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Wugen's next move

See what Strategic adds

Wugen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.